| | |
每股
|
| |
合计
|
| ||||||
首次公开募股价格
|
| | | $ | 10.00 | | | | | $ | 35,200,000 | | |
承保折扣和佣金(1)
|
| | | $ | 0.70 | | | | | $ | 2,464,000 | | |
未扣除费用的收益给我们
|
| | | $ | 9.30 | | | | | $ | 32,736,000 | | |
|
关于本招股说明书
|
| | | | II | | |
|
招股说明书摘要
|
| | | | 1 | | |
|
风险因素摘要
|
| | | | 3 | | |
|
产品
|
| | | | 7 | | |
|
汇总合并财务数据
|
| | | | 8 | | |
|
有关前瞻性陈述的特别说明
|
| | | | 9 | | |
|
风险因素
|
| | | | 11 | | |
|
收益使用情况
|
| | | | 49 | | |
|
股利政策
|
| | | | 50 | | |
|
稀释
|
| | | | 51 | | |
|
大写
|
| | | | 53 | | |
|
管理层对财务状况和经营成果的讨论和分析
|
| | | | 55 | | |
|
业务
|
| | | | 69 | | |
|
管理
|
| | | | 88 | | |
|
高管薪酬
|
| | | | 96 | | |
|
主要股东
|
| | | | 103 | | |
|
某些关系和关联方交易
|
| | | | 104 | | |
|
股本说明
|
| | | | 106 | | |
|
有资格未来出售的股票
|
| | | | 111 | | |
|
美国联邦所得税对非美国持有者的重大后果
|
| | | | 113 | | |
|
承销
|
| | | | 116 | | |
|
法律事务
|
| | | | 121 | | |
|
专家
|
| | | | 121 | | |
|
在哪里可以找到更多信息
|
| | | | 121 | | |
|
财务报表索引
|
| | | | F-1 | | |
| | |
(未审核)
截至6月30日的6个月 |
| |
截至2013年12月31日的年度
|
| ||||||||||||||||||
| | |
2021
|
| |
2020
|
| |
2020
|
| |
2019
|
| ||||||||||||
产品收入,净额
|
| | | $ | 26,007 | | | | | $ | 21,361 | | | | | $ | 44,531 | | | | | $ | 34,921 | | |
运营费用 | | | | | | | | | | | | | | | | | | | | | | | | | |
- 产品销售成本产品收入
|
| | | | 11,392 | | | | | | 6,934 | | | | | | 14,594 | | | | | | 10,532 | | |
研发
|
| | | | 29 | | | | | | — | | | | | | — | | | | | | — | | |
获得研发 - 许可证
|
| | | | 13,743 | | | | | | — | | | | | | — | | | | | | — | | |
销售、一般和行政
|
| | | | 14,021 | | | | | | 10,441 | | | | | | 22,086 | | | | | | 19,130 | | |
总运营费用
|
| | | | 39,185 | | | | | | 17,375 | | | | | | 36,680 | | | | | | 29,662 | | |
运营收入(亏损)
|
| | | | (13,178) | | | | | | 3,986 | | | | | | 7,851 | | | | | | 5,259 | | |
其他费用
|
| | | | | | | | | | | | | | | | | | | | | | | | |
利息支出
|
| | | | 1,563 | | | | | | 305 | | | | | | 698 | | | | | | 255 | | |
衍生负债公允价值变动
|
| | | | 182 | | | | | | — | | | | | | — | | | | | | — | | |
其他费用合计
|
| | | | 1,745 | | | | | | 305 | | | | | | 698 | | | | | | 255 | | |
所得税前收入(亏损)
|
| | | | (14,923) | | | | | | 3,681 | | | | | | 7,153 | | | | | | 5,004 | | |
所得税(福利)费用
|
| | | | (3,326) | | | | | | 929 | | | | | | 1,870 | | | | | | 1,379 | | |
净(亏损)收入
|
| | | $ | (11,597) | | | | | $ | 2,752 | | | | | $ | 5,283 | | | | | $ | 3,625 | | |
每股普通股净(亏损)收入 - Basic
|
| | | $ | (1.27) | | | | | $ | 0.30 | | | | | $ | 0.58 | | | | | $ | 0.40 | | |
稀释后的每股普通股净(亏损)收益 -
|
| | | $ | (1.27) | | | | | $ | 0.25 | | | | | $ | 0.49 | | | | | $ | 0.36 | | |
加权平均已发行普通股 - Basic
|
| | | | 9,159,841 | | | | | | 9,133,333 | | | | | | 9,135,985 | | | | | | 9,133,333 | | |
加权平均已发行普通股 - 稀释
|
| | | | 9,159,841 | | | | | | 10,826,279 | | | | | | 10,836,122 | | | | | | 10,075,804 | | |
| | |
(未审核)
截至2021年6月30日 |
| |
12月31日
2020 |
| ||||||||||||
| | |
实际
|
| |
形式(1)
|
| ||||||||||||
资产负债表数据 | | | | | | | | | | | | | | | | | | | |
现金
|
| | | $ | 12,176 | | | | | $ | 58,977 | | | | | $ | 8,246 | | |
营运资金
|
| | | | 9,064 | | | | | | 56,365 | | | | | | 7,182 | | |
总资产
|
| | | | 72,725 | | | | | | 119,526 | | | | | | 51,906 | | |
总负债
|
| | | | 73,517 | | | | | | 55,393 | | | | | | 41,614 | | |
普通股和A类普通股
|
| | | | 1 | | | | | | 2 | | | | | | 1 | | |
(累计亏损)留存收益
|
| | | | (6,477) | | | | | | (6,477) | | | | | | 5,171 | | |
股东(赤字)总股本
|
| | | | (792) | | | | | | 64,133 | | | | | | 10,292 | | |
|
每股首次公开募股价格
|
| | | | | | | | | $ | 10.00 | | |
|
2021年6月30日每股有形账面净值(亏损)
|
| | | $ | (1.58) | | | | |||||
|
可归因于交易调整的每股有形账面净值增加(1)
|
| | | $ | 3.05 | | | | |||||
|
参与此次发行的投资者每股有形账面净值增加。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | $ | 1.60 | | | | |||||
|
本次发行后调整后的每股有形账面净值
|
| | | | | | | | | $ | 3.07 | | |
|
对参与此次发行的新投资者每股摊薄
|
| | | | | | | | | $ | 6.93 | | |
| | |
号码
|
| |
%
|
| |
(千)
|
| |
加权
每股平均 |
| ||||||||||||||||||
|
金额
|
| |
百分比
|
| ||||||||||||||||||||||||||
现有股东
|
| | | | 9,161,333 | | | | | | 56% | | | | | $ | 0.92 | | | | | | 0% | | | | | $ | 0.00 | | |
参与发售的投资者(1)
|
| | | | 7,279,911 | | | | | | 44% | | | | | | 69,452 | | | | | | 100% | | | | | $ | 9.54 | | |
| | | | | 16,441,244 | | | | | | 100% | | | | | $ | 69,453 | | | | | | 100% | | | | | $ | 4.22 | | |
| | |
截至2021年6月30日
|
| |||||||||||||||
| | |
实际
|
| |
调整后的
|
| |
形式
|
| |||||||||
现金 | | | | $ | 12,176 | | | | | $ | 27,591 | | | | | $ | 58,977 | | |
应计费用,关联方
|
| | | | 500 | | | | | | — | | | | | | — | | |
分期付款 - 许可证,短期(扣除债务折扣639美元)
2021年6月30日) |
| | | | 3,861 | | | | | | 3,861 | | | | | | 3,861 | | |
应付票据关联方
|
| | | | 5,245 | | | | | | — | | | | | | — | | |
分期付款 - 许可证,长期(扣除565美元的债务折扣)
2021年6月30日) |
| | | | 6,435 | | | | | | 6,435 | | | | | | 6,435 | | |
可转换优先股结算票据(扣除债务折价1,824美元后为
2021年6月30日) |
| | | | 13,092 | | | | | | — | | | | | | — | | |
衍生权证责任
|
| | | | 4,287 | | | | | | 5,000 | | | | | | 5,000 | | |
股东(亏损)/股权 | | | | | | | | | | | | | | | | | | | |
普通股,面值0.0001美元,授权股份50,000,000股,截至2021年6月30日已发行和已发行股票分别为3,161,333股,6,921,244股和10,441,244股,分别为实际、调整和预计发行
|
| | | | — | | | | | | 1 | | | | | | 1 | | |
截至2021年6月30日,普通股 - A类,面值0.0001美元,授权股份5000万股,已发行和已发行股份600万股
|
| | | | 1 | | | | | | — | | | | | | 1 | | |
新增实收资本
|
| | | | 5,684 | | | | | | 39,223 | | | | | | 70,608 | | |
留存收益(累计亏损)
|
| | | | (6,477) | | | | | | (6,477) | | | | | | (6,477) | | |
股东权益总额
|
| | | | (793) | | | | | | 32,747 | | | | | | 64,133 | | |
总市值
|
| | | $ | 32,627 | | | | | $ | 48,043 | | | | | $ | 79,429 | | |
(千美元)
|
| |
截至2010年12月31日的年度
|
| |
更改
|
| ||||||||||||||||||
|
2020
|
| |
2019
|
| |
$
|
| |
%
|
| ||||||||||||||
产品收入,净额。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | $ | 44,531 | | | | | $ | 34,921 | | | | | $ | 9,610 | | | | | | 28% | | |
运营费用 | | | | | | | | | | | | | | | | | | | | | | | | | |
- 产品收入的售出商品成本。。。。。。。。。。。。。。。。。。。
|
| | | | 14,594 | | | | | | 10,532 | | | | | | 4,062 | | | | | | 39% | | |
销售、一般和管理。。。。。。。。。。。。。。。。。。。。。。
|
| | | | 22,086 | | | | | | 19,130 | | | | | | 2,956 | | | | | | 15% | | |
总运营费用。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | | 36,680 | | | | | | 29,662 | | | | | | 7,018 | | | | | | 24% | | |
运营收入。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | | 7,851 | | | | | | 5,259 | | | | | | 2,592 | | | | | | 49% | | |
其他费用 | | | | | | | | | | | | | | | | | | | | | | | | | |
利息支出。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | | 698 | | | | | | 255 | | | | | | 443 | | | | | | 174% | | |
其他费用合计
|
| | | | 698 | | | | | | 255 | | | | | | 443 | | | | | | 174% | | |
所得税前收入。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | | 7,153 | | | | | | 5,004 | | | | | | 2,149 | | | | | | 43% | | |
所得税费用。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | | 1,870 | | | | | | 1,379 | | | | | | 491 | | | | | | 36% | | |
净收入。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | $ | 5,283 | | | | | $ | 3,625 | | | | | $ | 1,659 | | | | | | 46% | | |
每股普通股净收入 - Basic。。。。。。。。。。。。。。。。。。。。。
|
| | | $ | 0.58 | | | | | $ | 0.40 | | | | | $ | 0.18 | | | | | | 46% | | |
稀释后的每股普通股净收入 - 。。。。。。。。。。。。。。。。。。。。
|
| | | $ | 0.49 | | | | | $ | 0.36 | | | | | $ | 0.13 | | | | | | 36% | | |
(千美元)
|
| |
截至2013年12月31日的年度
|
| |
更改
|
| ||||||||||||||||||
|
2020
|
| |
2019
|
| |
$
|
| |
%
|
| ||||||||||||||
Targadox®。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | $ | 30,708 | | | | | $ | 28,068 | | | | | $ | 2,640 | | | | | | 9% | | |
Ximino®。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | | 9,518 | | | | | | 3,642 | | | | | | 5,876 | | | | | | 161% | | |
Exelderm®。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | | 4,453 | | | | | | 2,867 | | | | | | 1,586 | | | | | | 55% | | |
其他产品收入。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | | (148) | | | | | | 344 | | | | | | (492) | | | | | | NM | | |
产品总收入,净额。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | $ | 44,531 | | | | | $ | 34,921 | | | | | $ | 9,610 | | | | | | 28% | | |
| | |
返回
|
| |
优惠券
|
| |
托管
关怀/政府 返点 |
| |
合计
|
| ||||||||||||
2018年12月31日的余额
|
| | | $ | 3,065 | | | | | $ | 1,599 | | | | | $ | — | | | | | $ | 4,664 | | |
与当期销售相关的当前拨备
|
| | | | 2,925 | | | | | | 42,374 | | | | | | 1,985 | | | | | | 47,284 | | |
签发给第三方的支票/信用证
|
| | | | (574) | | | | | | (37,567) | | | | | | — | | | | | | (38,141) | | |
在负债账户之间重新分类
|
| | | | (900) | | | | | | 900 | | | | | | — | | | | | | — | | |
2019年12月31日的余额
|
| | | $ | 4,516 | | | | | $ | 7,306 | | | | | $ | 1,985 | | | | | $ | 13,807 | | |
与当期销售相关的当期拨备(调整)
|
| | | | 1,294 | | | | | | 100,168 | | | | | | (537) | | | | | | 100,925 | | |
签发给第三方的支票/信用证
|
| | | | (2,130) | | | | | | (95,805) | | | | | | (1,348) | | | | | | (99,283) | | |
在负债账户之间重新分类
|
| | | | (1,100) | | | | | | 1,100 | | | | | | — | | | | | | — | | |
2020年12月31日的余额
|
| | | $ | 2,580 | | | | | $ | 12,769 | | | | | $ | 100 | | | | | $ | 15,449 | | |
(千美元,每股数据除外)
|
| |
(未审核)
截至6个月 06月30日 |
| |
更改
|
| ||||||||||||||||||
|
2021
|
| |
2020
|
| |
$
|
| |
%
|
| ||||||||||||||
产品收入,净额
|
| | | $ | 26,007 | | | | | $ | 21,361 | | | | | $ | 4,646 | | | | | | 22% | | |
运营费用 | | | | | | | | | | | | | | | | | | | | | | | | | |
- 产品销售成本产品收入
|
| | | | 11,392 | | | | | | 6,934 | | | | | | 4,458 | | | | | | 64% | | |
研发
|
| | | | 29 | | | | | | — | | | | | | 29 | | | | | | 100% | | |
获得研发 - 许可证
|
| | | | 13,743 | | | | | | — | | | | | | 13,743 | | | | | | 100% | | |
销售、一般和行政
|
| | | | 14,021 | | | | | | 10,441 | | | | | | 3,580 | | | | | | 34% | | |
总运营费用
|
| | | | 39,185 | | | | | | 17,375 | | | | | | 21,810 | | | | | | 126% | | |
运营收入(亏损)
|
| | | | (13,178) | | | | | | 3,986 | | | | | | (17,164) | | | | | | -431% | | |
其他费用 | | | | | | | | | | | | | | | | | | | | | | | | | |
利息支出
|
| | | | 1,563 | | | | | | 305 | | | | | | 1,258 | | | | | | 412% | | |
衍生负债公允价值变动
|
| | | | 182 | | | | | | — | | | | | | 182 | | | | | | 100% | | |
其他费用合计
|
| | | | 1,745 | | | | | | 305 | | | | | | 1,440 | | | | | | 472% | | |
所得税前收入(亏损)
|
| | | | (14,923) | | | | | | 3,681 | | | | | | (18,604) | | | | | | -505% | | |
所得税(福利)费用
|
| | | | (3,326) | | | | | | 929 | | | | | | (4,255) | | | | | | -458% | | |
净(亏损)收入
|
| | | $ | (11,597) | | | | | $ | 2,752 | | | | | $ | (14,349) | | | | | | -521% | | |
每股普通股净(亏损)收入 - Basic
|
| | | $ | (1.27) | | | | | $ | 0.30 | | | | | $ | (1.57) | | | | | | -520% | | |
稀释后的每股普通股净(亏损)收益 -
|
| | | $ | (1.27) | | | | | $ | 0.25 | | | | | $ | (1.52) | | | | | | -598% | | |
(千美元)
|
| |
(未审核)
截至6月30日的6个月 |
| |
更改
|
| ||||||||||||||||||
|
2021
|
| |
2020
|
| |
$
|
| |
%
|
| ||||||||||||||
Targadox® | | | | $ | 12,926 | | | | | $ | 14,981 | | | | | $ | (2,055) | | | | | | -14% | | |
Ximino® | | | | | 3,413 | | | | | | 4,823 | | | | | | (1,410) | | | | | | -29% | | |
Exelderm® | | | | | 2,953 | | | | | | 1,687 | | | | | | 1,266 | | | | | | 75% | | |
Accutane® | | | | | 2,141 | | | | | | — | | | | | | 2,141 | | | | | | 100% | | |
Qbrexza® | | | | | 4,568 | | | | | | — | | | | | | 4,568 | | | | | | 100% | | |
其他品牌收入
|
| | | | 6 | | | | | | (130) | | | | | | 136 | | | | | | -105% | | |
产品总收入
|
| | | $ | 26,007 | | | | | $ | 21,361 | | | | | $ | 4,646 | | | | | | 22% | | |
| | |
返回
|
| |
优惠券
|
| |
托管
关怀/政府 返点 |
| |
合计
|
| ||||||||||||
2020年12月31日的余额
|
| | | $ | 2,580 | | | | | $ | 12,769 | | | | | $ | 100 | | | | | $ | 15,449 | | |
与当期销售相关的当前拨备
|
| | | | 1,428 | | | | | | 68,591 | | | | | | 2,275 | | | | | | 72,294 | | |
签发给第三方的支票/信用证
|
| | | | (1,594) | | | | | | (64,148) | | | | | | (1,293) | | | | | | (67,035) | | |
在负债账户之间重新分类
|
| | | | (315) | | | | | | 315 | | | | | | — | | | | | | — | | |
2021年6月30日的余额
|
| | | $ | 2,099 | | | | | $ | 17,527 | | | | | $ | 1,082 | | | | | $ | 20,708 | | |
(千美元)
|
| |
截至2010年12月31日的年度
|
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
现金总额(用于)/提供者: | | | | | | | | | | | | | |
经营活动。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | $ | 5,132 | | | | | $ | 9,018 | | |
投资活动。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | | (1,200) | | | | | | (2,400) | | |
融资活动。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | | (487) | | | | | | (3,551) | | |
现金净增长。。。。。。。。。。。。。。。。。。。。。。。。。。。。。。
|
| | | $ | 3,445 | | | | | $ | 3,067 | | |
(千美元)
|
| |
(未审核)
截至6月30日的6个月 |
| | ||||||||||||||
|
2021
|
| |
2020
|
| |
更改
|
| |||||||||||
经营活动提供的净现金(用于)
|
| | | $ | (6,077) | | | | | $ | 1,149 | | | | | $ | (7,226) | | |
融资活动提供的净现金
|
| | | | 10,007 | | | | | | — | | | | | | 10,007 | | |
现金净增长
|
| | | $ | 3,930 | | | | | $ | 1,149 | | | | | $ | 2,781 | | |
| | |
截止6个月
|
| |
截至2013年12月31日的年度
|
| ||||||||||||||||||
(千美元)
|
| |
2021年6月30日
|
| |
2020年6月30日
|
| |
2020
|
| |
2019
|
| ||||||||||||
净(亏损)收入
|
| | | $ | (11,597) | | | | | $ | 2,752 | | | | | $ | 5,283 | | | | | $ | 3,625 | | |
所得税(福利)费用
|
| | | | (3,326) | | | | | | 929 | | | | | | 1,870 | | | | | | 1,379 | | |
非现金利息
|
| | | | 1,025 | | | | | | 305 | | | | | | 698 | | | | | | 255 | | |
摊销许可证
|
| | | | 1,325 | | | | | | 710 | | | | | | 1,420 | | | | | | 1,174 | | |
债务贴现摊销
|
| | | | 270 | | | | | | — | | | | | | — | | | | | | — | | |
折旧
|
| | | | — | | | | | | 3 | | | | | | 5 | | | | | | 5 | | |
非GAAP EBITDA
|
| | | $ | (12,303) | | | | | $ | 4,699 | | | | | $ | 9,276 | | | | | $ | 6,438 | | |
股票薪酬
|
| | | | 33 | | | | | | 99 | | | | | | 153 | | | | | | 240 | | |
配售代理权证公允价值变动
|
| | | | 182 | | | | | | — | | | | | | — | | | | | | — | | |
研发许可证非现金或有付款
|
| | | | 3,743 | | | | | | — | | | | | | — | | | | | | — | | |
Qbrexza库存提升
|
| | | | 1,238 | | | | | | — | | | | | | — | | | | | | — | | |
严重
|
| | | | 260 | | | | | | — | | | | | | — | | | | | | — | | |
非GAAP调整后EBITDA
|
| | | $ | (6,837)(1) | | | | | $ | 4,798(2) | | | | | $ | 9,492(2) | | | | | $ | 6,678 | | |
|
产品收购的净销售额里程碑
|
| | | $ | 303,000 | | |
|
发展里程碑
|
| | | | 38,500 | | |
|
或有付款
|
| | | | 5,000 | | |
|
获得应计研发许可证
|
| | | | 8,000 | | |
| | |
未来租赁
责任 |
| |||
截至2021年12月31日的6个月
|
| | | $ | 48 | | |
截至2022年12月31日的年度
|
| | | | 100 | | |
合计
|
| | | | 148 | | |
减去:现值折扣
|
| | | | (5) | | |
经营性租赁负债
|
| | | $ | 143 | | |
名称
|
| |
年龄
|
| |
职位
|
| |||
克劳德·马拉维
|
| | | | 55 | | | |
总裁、首席执行官兼董事
|
|
Ernie de Paolantonio
|
| | | | 68 | | | | 首席财务官 | |
名称
|
| |
年龄
|
| |
职位
|
| |||
罗伯特·内文
|
| | | | 53 | | | | 首席商务官 | |
拉姆齐·阿卢什
|
| | | | 36 | | | | 总法律顾问 | |
Andrew Zwible
|
| | | | 41 | | | | 运营副总裁 | |
欧内斯特·加尔万
|
| | | | 59 | | | |
市场营销和战略副总裁
|
|
名称
|
| |
年龄
|
| |
职位
|
| |||
医学博士林赛·A·罗森沃尔德
|
| | | | 66 | | | | 董事会执行主席 | |
克劳德·马拉维
|
| | | | 55 | | | |
总裁兼首席执行官兼董事
|
|
尼尔·赫斯科维茨
|
| | | | 64 | | | | 导演 | |
医学博士杰夫·佩利
|
| | | | 53 | | | | 导演 | |
贾斯汀·史密斯
|
| | | | 47 | | | | 导演 | |
米兰达·托莱达诺
|
| | | | 44 | | | | 导演 | |
姓名和主要职务
|
| |
年
|
| |
工资
($) |
| |
奖金
($) |
| |
库存
奖项(1) ($) |
| |
所有其他
($) |
| |
($)
|
| ||||||||||||||||||
克劳德·马拉维。 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
首席执行官
|
| | | | 2020 | | | | | $ | 450,000 | | | | | $ | 450,000 | | | | | $ | 1,193,061 | | | | | $ | 827 | | | | | $ | 2,093,888 | | |
Nirav Jhaveri(2) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
首席财务官
|
| | | | 2020 | | | | | | 281,194 | | | | | | — | | | | | | 219,050 | | | | | | 680 | | | | | | 500,924 | | |
| | |
选项奖(1)
|
| |
股票奖励(2)
|
| ||||||||||||||||||||||||||||||||||||
名称
|
| |
授予
日期 |
| |
数量
证券 底层 未锻炼 选项 可锻炼 |
| |
数量
证券 底层 未锻炼 选项 不可行使 |
| |
选项
练习 价格(3) |
| |
选项
过期 日期 |
| |
数量
股份 库存 那个 没有 归属 |
| |
市场
值 共享 没有 归属 |
| |||||||||||||||||||||
克劳德·马拉维
|
| | | | 10/19/2015 | | | | | | 1,250,000 | | | | | | — | | | | | $ | 0.065 | | | | | | 10/19/2025 | | | | | | — | | | | | | — | | |
| | | | | 09/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 354,024 | | | | | $ | 1,193,061 | | |
Nirav Jhaveri
|
| | | | 06/17/2019 | | | | | | 13,333 | | | | | | 6,667 | | | | | $ | 1.390 | | | | | | | | | | | | | | | | | | | | |
| | | | | 09/24/2020 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 65,000 | | | | | $ | 219,050 | | |
| | |
数量
个共享 受益 拥有 之前的 至产品 |
| |
百分比
个共享 实益拥有的 |
| ||||||||||||
受益人姓名
|
| |
之前的
这个 提供服务 |
| |
之后的
这个 提供服务 |
| ||||||||||||
5%及更大股东: | | | | | | | | | | | | | | | | | | | |
堡垒生物技术公司(1)
|
| | | | 8,500,000 | | | | | | 92.8% | | | | | | 51.7% | | |
被任命的高管和董事: | | | | | | | | | | | | | | | | | | | |
Lindsay A.Rosenwald,M.D.(2)
|
| | | | 500,000 | | | | | | 5.5% | | | | | | 3.0% | | |
Claude Maraoui(3)
|
| | | | 1,450,000 | | | | | | 15.8% | | | | | | 8.8% | | |
尼尔·赫斯科维茨
|
| | | | — | | | | | | | | | | | | | | |
杰夫·佩利医学博士
|
| | | | — | | | | | | | | | | |||||
贾斯汀·史密斯
|
| | | | — | | | | | | | | | | | | | | |
米兰达·托莱达诺
|
| | | | — | | | | | | | | | | | | | | |
所有高管和董事作为一个群体
|
| | | | 1,950,000 | | | | | | 21.3% | | | | | | 11.9% | | |
承销商
|
| |
股份数量
|
| |||
B.莱利证券公司
|
| | | | 2,992,000 | | |
Roth Capital Partners,LLC
|
| | | | 528,000 | | |
合计
|
| | | | 3,520,000 | | |
| | |
每股
|
| |
不含
的合计
练习 结束- 分配 |
| |
总计
练习 结束- 分配 |
| |||||||||
公开发行价
|
| | | $ | 10.00 | | | | | $ | 35,200,000 | | | | | $ | 40,480,000 | | |
承保折扣和佣金
|
| | | $ | 0.70 | | | | | $ | 2,464,000 | | | | | $ | 2,833,600 | | |
未向我们支付费用前的收益
|
| | | $ | 9.30 | | | | | $ | 32,736,000 | | | | | $ | 37,646,400 | | |
|
截至2021年6月30日(未经审计)和2020年12月31日的简明合并资产负债表
|
| | | | F-2 | | |
|
截至2021年6月30日的三个月和六个月的简明综合经营报表
和2020年 |
| | | | F-3 | | |
|
截至2021年6月30日和2020年6月30日的三个月和六个月股东权益(赤字)简明综合变动表
|
| | | | F-4 | | |
|
截至2021年6月30日和2020年6月30日的6个月现金流量表简明合并报表
|
| | | | F-6 | | |
|
精简合并财务报表附注
|
| | | | F-7 | | |
|
独立注册会计师事务所报告
|
| | | | F-26 | | |
|
截至2020年12月31日和2019年12月31日的合并资产负债表
|
| | | | F-27 | | |
|
截至2020年12月31日和2019年12月31日的三个年度的合并经营报表
|
| | | | F-28 | | |
|
截至2020年12月31日和2019年12月31日止年度股东权益(赤字)变动表
|
| | | | F-29 | | |
|
截至2020年12月31日和2019年12月31日的三个年度的合并现金流量表
|
| | | | F-30 | | |
|
合并财务报表附注
|
| | | | F-31 | | |
| | |
06月30日
2021 |
| |
12月31日
2020 |
| ||||||
| | |
(未审核)
|
| | | | | | | |||
资产 | | | | | | | | | | | | | |
流动资产 | | | | | | | | | | | | | |
现金
|
| | | $ | 12,176 | | | | | $ | 8,246 | | |
扣除准备金后的应收账款
|
| | | | 26,193 | | | | | | 23,928 | | |
库存
|
| | | | 14,315 | | | | | | 1,404 | | |
预付费用和其他流动资产
|
| | | | 789 | | | | | | 1,664 | | |
流动资产总额
|
| | | | 53,473 | | | | | | 35,242 | | |
长期资产 | | | | | | | | | | | | | |
无形资产净值
|
| | | | 13,701 | | | | | | 15,029 | | |
经营性租赁使用权资产,净额
|
| | | | 133 | | | | | | 175 | | |
递延税金资产
|
| | | | 5,269 | | | | | | 1,454 | | |
其他资产
|
| | | | 149 | | | | | | 6 | | |
长期资产总额
|
| | | | 19,252 | | | | | | 16,664 | | |
总资产
|
| | | $ | 72,725 | | | | | $ | 51,906 | | |
负债和股东权益(赤字) | | | | | | | | | | | | | |
流动负债 | | | | | | | | | | | | | |
应付帐款
|
| | | $ | 4,245 | | | | | $ | 1,839 | | |
应收账款、关联方
|
| | | | 345 | | | | | | 117 | | |
应计费用
|
| | | | 35,364 | | | | | | 21,498 | | |
应计费用,关联方
|
| | | | 500 | | | | | | — | | |
分期付款 - 许可证,短期(扣除639美元和778美元的债务折扣)
分别为2021年6月30日和2020年12月31日) |
| | | | 3,861 | | | | | | 4,522 | | |
短期经营租赁负债
|
| | | | 94 | | | | | | 85 | | |
流动负债总额
|
| | | | 44,409 | | | | | | 28,061 | | |
应付所得税
|
| | | | — | | | | | | 99 | | |
应付票据关联方
|
| | | | 5,245 | | | | | | 5,220 | | |
分期付款 - 许可证,长期(分别扣除截至2021年6月30日和2020年12月31日的债务折扣净额565美元和863美元)
|
| | | | 6,435 | | | | | | 8,137 | | |
可转换A类优先股结算票据(截至2021年6月30日债务折价净额为1824美元)
|
| | | | 13,092 | | | | | | — | | |
衍生权证责任
|
| | | | 4,287 | | | | | | — | | |
长期经营租赁负债
|
| | | | 49 | | | | | | 97 | | |
总负债
|
| | | | 73,517 | | | | | | 41,614 | | |
承付款和或有事项 | | | | | | | | | | | | | |
股东权益(亏损) | | | | | | | | | | | | | |
截至2021年6月30日和2020年12月31日,普通股,面值0.0001美元,授权股份50,000,000股,已发行和已发行股票分别为3,161,333股和3,151,333股
|
| | | | — | | | | | | — | | |
截至2021年6月30日和2020年12月31日,普通股 - A类,面值0.0001美元,授权股份5000万股,已发行和已发行股份600万股
|
| | | | 1 | | | | | | 1 | | |
新增实收资本
|
| | | | 5,684 | | | | | | 5,171 | | |
留存收益(累计亏损)
|
| | | | (6,477) | | | | | | 5,120 | | |
股东权益总额(亏损)
|
| | | | (792) | | | | | | 10,292 | | |
总负债和股东权益(赤字)
|
| | | $ | 72,725 | | | | | $ | 51,906 | | |
| | |
截至6月30日的三个月
|
| |
截至6月30日的6个月
|
| ||||||||||||||||||
| | |
2021
|
| |
2020
|
| |
2021
|
| |
2020
|
| ||||||||||||
产品收入,净额
|
| | | $ | 15,288 | | | | | $ | 9,415 | | | | | $ | 26,007 | | | | | $ | 21,361 | | |
运营费用 | | | | | | | | | | | | | | | | | | | | | | | | | |
- 产品销售成本产品收入
|
| | | | 7,484 | | | | | | 3,124 | | | | | | 11,392 | | | | | | 6,934 | | |
研发
|
| | | | 29 | | | | | | — | | | | | | 29 | | | | | | — | | |
研发 - 许可证
已收购 |
| | | | 13,743 | | | | | | — | | | | | | 13,743 | | | | | | — | | |
销售、一般和行政
|
| | | | 7,795 | | | | | | 4,752 | | | | | | 14,021 | | | | | | 10,441 | | |
总运营费用
|
| | | | 29,051 | | | | | | 7,876 | | | | | | 39,185 | | | | | | 17,375 | | |
运营收入(亏损)
|
| | | | (13,763) | | | | | | 1,539 | | | | | | (13,178) | | | | | | 3,986 | | |
其他费用 | | | | | | | | | | | | | | | | | | | | | | | | | |
利息支出
|
| | | | 1,342 | | | | | | 155 | | | | | | 1,563 | | | | | | 305 | | |
衍生负债公允价值变动
|
| | | | 182 | | | | | | — | | | | | | 182 | | | | | | — | | |
其他费用合计
|
| | | | 1,524 | | | | | | 155 | | | | | | 1,745 | | | | | | 305 | | |
所得税前收入(亏损)
|
| | | | (15,287) | | | | | | 1,384 | | | | | | (14,923) | | | | | | 3,681 | | |
所得税(福利)费用
|
| | | | (3,422) | | | | | | 929 | | | | | | (3,326) | | | | | | 929 | | |
净(亏损)收入
|
| | | $ | (11,865) | | | | | $ | 455 | | | | | $ | (11,597) | | | | | $ | 2,752 | | |
每股普通股净(亏损)收入 - Basic
|
| | | $ | (1.30) | | | | | $ | 0.05 | | | | | $ | (1.27) | | | | | $ | 0.30 | | |
稀释后的每股普通股净(亏损)收益 -
|
| | | $ | (1.30) | | | | | $ | 0.04 | | | | | $ | (1.27) | | | | | $ | 0.25 | | |
加权平均已发行普通股 - Basic
|
| | | | 9,161,333 | | | | | | 9,133,333 | | | | | | 9,159,841 | | | | | | 9,133,333 | | |
加权平均已发行普通股 - 稀释
|
| | | | 9,161,333 | | | | | | 10,832,990 | | | | | | 9,159,841 | | | | | | 10,826,279 | | |
| | |
普通股
|
| |
普通股A
|
| |
其他
实收 大写 |
| |
保留
收入 (累计 赤字) |
| |
合计
股东的 股权/ (赤字) |
| |||||||||||||||||||||||||||
|
个共享
|
| |
金额
|
| |
个共享
|
| |
金额
|
| ||||||||||||||||||||||||||||||||
截至2020年12月31日的余额
|
| | | | 3,151,333 | | | | | $ | — | | | | | | 6,000,000 | | | | | $ | 1 | | | | | $ | 5,171 | | | | | $ | 5,120 | | | | | $ | 10,292 | | |
股票薪酬
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 33 | | | | | | — | | | | | | 33 | | |
行使现金期权
|
| | | | 10,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | 7 | | | | | | — | | | | | | 7 | | |
出资额 - 清偿关联方应付
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 473 | | | | | | — | | | | | | 473 | | |
净亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (11,597) | | | | | | (11,597) | | |
截至2021年6月30日的余额(未经审计)
|
| | | | 3,161,333 | | | | | $ | — | | | | | | 6,000,000 | | | | | $ | 1 | | | | | $ | 5,684 | | | | | $ | (6,477) | | | | | $ | (792) | | |
| | |
普通股
|
| |
普通股A
|
| |
其他
实收 大写 |
| |
保留
收入 (累计 赤字) |
| |
合计
股东的 股权/ (赤字) |
| |||||||||||||||||||||||||||
|
个共享
|
| |
金额
|
| |
个共享
|
| |
金额
|
| ||||||||||||||||||||||||||||||||
截至2021年3月31日的余额(未经审计)
|
| | | | 3,161,333 | | | | | $ | — | | | | | | 6,000,000 | | | | | $ | 1 | | | | | $ | 5,378 | | | | | $ | 5,388 | | | | | $ | 10,767 | | |
股票薪酬
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 11 | | | | | | — | | | | | | 11 | | |
出资额 - 清偿关联方应付
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 295 | | | | | | — | | | | | | 295 | | |
净亏损
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (11,865) | | | | | | (11,865) | | |
截至2021年6月30日的余额(未经审计)
|
| | | | 3,161,333 | | | | | $ | — | | | | | | 6,000,000 | | | | | $ | 1 | | | | | $ | 5,684 | | | | | $ | (6,477) | | | | | $ | (792) | | |
| | |
普通股
|
| |
普通股A
|
| |
其他
实收 大写 |
| |
保留
收入 (累计 赤字) |
| |
合计
股东的 股权 |
| |||||||||||||||||||||||||||
|
个共享
|
| |
金额
|
| |
个共享
|
| |
金额
|
| ||||||||||||||||||||||||||||||||
截至2019年12月31日的余额
|
| | | | 3,133,333 | | | | | $ | — | | | | | | 6,000,000 | | | | | $ | 1 | | | | | $ | 2,914 | | | | | $ | (163) | | | | | $ | 2,752 | | |
股票薪酬
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 99 | | | | | | — | | | | | | 99 | | |
出资额 - 清偿关联方应付
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 854 | | | | | | — | | | | | | 854 | | |
净收入
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 2,752 | | | | | | 2,752 | | |
截至2020年6月30日的余额(未经审计)
|
| | | | 3,133,333 | | | | | $ | — | | | | | | 6,000,000 | | | | | $ | 1 | | | | | $ | 3,867 | | | | | $ | 2,589 | | | | | $ | 6,457 | | |
| | |
普通股
|
| |
普通股A
|
| |
其他
实收 大写 |
| |
保留
收入 |
| |
合计
股东的 股权 |
| |||||||||||||||||||||||||||
|
个共享
|
| |
金额
|
| |
个共享
|
| |
金额
|
| ||||||||||||||||||||||||||||||||
截至2020年3月31日的余额(未经审计)
|
| | | | 3,133,333 | | | | | $ | — | | | | | | 6,000,000 | | | | | $ | 1 | | | | | $ | 2,973 | | | | | $ | 2,134 | | | | | $ | 5,108 | | |
股票薪酬
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 40 | | | | | | — | | | | | | 40 | | |
出资额 - 清偿关联方应付
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 854 | | | | | | — | | | | | | 854 | | |
净收入
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 455 | | | | | | 455 | | |
截至2020年6月30日的余额(未经审计)
|
| | | | 3,133,333 | | | | | $ | — | | | | | | 6,000,000 | | | | | $ | 1 | | | | | $ | 3,867 | | | | | $ | 2,589 | | | | | $ | 6,457 | | |
| | |
截至6月30日的6个月
|
| |||||||||
|
2021
|
| |
2020
|
| ||||||||
经营活动的现金流 | | | | | | | | | | | | | |
净(亏损)收入
|
| | | $ | (11,597) | | | | | $ | 2,752 | | |
调整以调整净亏损与经营活动中使用的净现金: | | | | | | | | | | | | | |
折旧费
|
| | | | — | | | | | | 3 | | |
坏账(准备金)费用
|
| | | | (57) | | | | | | 76 | | |
非现金利息支出
|
| | | | 1,025 | | | | | | 305 | | |
债务贴现摊销
|
| | | | 270 | | | | | | — | | |
许可费摊销
|
| | | | 1,325 | | | | | | 710 | | |
经营性租赁使用权资产摊销
|
| | | | 42 | | | | | | 45 | | |
股票薪酬
|
| | | | 33 | | | | | | 99 | | |
递延税金(福利)拨备
|
| | | | (3,414) | | | | | | 44 | | |
应缴关联方所得税清缴
|
| | | | 72 | | | | | | 885 | | |
衍生负债公允价值变动
|
| | | | 182 | | | | | | — | | |
研发-获得许可证,费用
|
| | | | 3,743 | | | | | | — | | |
经营性资产和负债变动:
|
| | | | | | | | | | | | |
应收账款
|
| | | | (2,208) | | | | | | 1,692 | | |
库存
|
| | | | (12,911) | | | | | | (351) | | |
预付费用和其他流动资产
|
| | | | 950 | | | | | | 100 | | |
其他资产
|
| | | | (143) | | | | | | (200) | | |
应付帐款
|
| | | | 2,131 | | | | | | (607) | | |
应收账款、关联方
|
| | | | 252 | | | | | | 27 | | |
应计费用
|
| | | | 13,866 | | | | | | (4,372) | | |
应计费用,关联方
|
| | | | 500 | | | | | | — | | |
应付所得税
|
| | | | (99) | | | | | | (14) | | |
租赁负债
|
| | | | (39) | | | | | | (45) | | |
经营活动提供的净现金(用于)
|
| | | | (6,077) | | | | | | 1,149 | | |
融资活动产生的现金流 | | | | | | | | | | | | | |
期权行使收益
|
| | | | 7 | | | | | | — | | |
支付应付许可证票据
|
| | | | (2,800) | | | | | | — | | |
可转换优先股收益
|
| | | | 14,332 | | | | | | — | | |
支付与可转换优先股相关的债务发行成本
|
| | | | (1,532) | | | | | | — | | |
融资活动提供的净现金
|
| | | | 10,007 | | | | | | — | | |
现金净增长
|
| | | | 3,930 | | | | | | 1,149 | | |
期初现金
|
| | | | 8,246 | | | | | | 4,801 | | |
期末现金
|
| | | $ | 12,176 | | | | | $ | 5,950 | | |
补充披露现金流信息: | | | | | | | | | | | | | |
缴纳所得税的现金
|
| | | $ | 157 | | | | | $ | 61 | | |
补充披露非现金融资和投资活动: | | | | | | | | | | | | | |
未偿债务发行成本
|
| | | $ | 200 | | | | | $ | — | | |
未付延期发售成本
|
| | | $ | 75 | | | | | $ | — | | |
与可转换优先股相关的衍生权证责任
|
| | | $ | 362 | | | | | $ | — | | |
应付关联方清偿涉及递延税金资产
|
| | | $ | 401 | | | | | $ | (31) | | |
| | |
06月30日
2021 |
| |
12月31日
2020 |
| ||||||
| | |
(未审核)
|
| | ||||||||
原材料
|
| | | $ | 4,907 | | | | | $ | — | | |
成品
|
| | | | 9,408 | | | | | | 1,404 | | |
总库存
|
| | | $ | 14,315 | | | | | $ | 1,404 | | |
| | |
使用寿命
(年) |
| |
06月30日
2021 |
| |
12月31日
2020 |
| ||||||
| | | | | |
(未审核)
|
| | ||||||||
租赁改进
|
| |
2
|
| | | $ | 11 | | | | | $ | 11 | | |
全部物业和设备
|
| | | | | | | 11 | | | | | | 11 | | |
减去:累计折旧
|
| | | | | | | (11) | | | | | | (11) | | |
财产和设备,净额
|
| | | | | | $ | — | | | | | $ | — | | |
| | |
预计有用
寿命(年) |
| |
06月30日
2021 |
| |
12月31日
2020 |
| ||||||
| | | | | |
(未审核)
|
| | ||||||||
Ceracade® | | |
3
|
| | | $ | 300 | | | | | $ | 300 | | |
Luxamendate® | | |
3
|
| | | | 50 | | | | | | 50 | | |
Targadox® | | |
3
|
| | | | 1,250 | | | | | | 1,250 | | |
Ximino® | | |
7
|
| | | | 7,134 | | | | | | 7,134 | | |
Exelderm® | | |
3
|
| | | | 1,600 | | | | | | 1,600 | | |
Accutane
|
| |
5
|
| | | | 4,727 | | | | | | 4,727 | | |
止痒产品(1)
|
| |
3
|
| | | | 3,942 | | | | | | 3,945 | | |
合计
|
| | | | | | | 19,003 | | | | | | 19,006 | | |
累计摊销
|
| | | | | | | (5,302) | | | | | | (3,977) | | |
无形资产净值
|
| | | | | | $ | 13,701 | | | | | $ | 15,029 | | |
| | |
Ximino®
|
| |
Exelderm®
|
| |
Accutane®
|
| |
合计
摊销 |
| ||||||||||||
截至2021年12月31日的6个月
|
| | | $ | 509 | | | | | $ | 167 | | | | | $ | 473 | | | | | $ | 1,149 | | |
2022年12月31日
|
| | | | 1,019 | | | | | | — | | | | | | 946 | | | | | | 1,965 | | |
2023年12月31日
|
| | | | 1,019 | | | | | | — | | | | | | 945 | | | | | | 1,964 | | |
2024年12月31日
|
| | | | 1,019 | | | | | | — | | | | | | 946 | | | | | | 1,965 | | |
2025年12月31日
|
| | | | 1,019 | | | | | | — | | | | | | 945 | | | | | | 1,964 | | |
此后
|
| | | | 595 | | | | | | — | | | | | | 157 | | | | | | 752 | | |
小计
|
| | | $ | 5,180 | | | | | $ | 167 | | | | | $ | 4,412 | | | | | $ | 9,759 | | |
尚未投入使用的资产
|
| | | | | | | | | | | | | | | | | | | | | | 3,942 | | |
合计
|
| | | $ | 5,180 | | | | | $ | 167 | | | | | $ | 4,412 | | | | | $ | 13,701 | | |
| | |
2021年6月30日
|
| |||
无风险利率
|
| | | | 0.87% | | |
预期股息收益率
|
| | | | — | | |
三年内的预期期限
|
| | | | 1.3 | | |
预期波动率
|
| | | | 50% | | |
| | |
2021年6月30日
|
|
折扣率
|
| |
30%
|
|
预期股息收益率
|
| |
—
|
|
预期期限
|
| |
3个月至5个月
|
|
| | |
截至2021年6月30日的公允价值计量
|
| |||||||||||||||||||||
|
一级
|
| |
二级
|
| |
第三级
|
| |
合计
|
| ||||||||||||||
负债 | | | | | | | | | | | | | | | | | | | | | | | | | |
衍生权证责任
|
| | | $ | — | | | | | | — | | | | | $ | 4,287 | | | | | $ | 4,287 | | |
合计
|
| | | $ | — | | | | | $ | — | | | | | $ | 4,287 | | | | | $ | 4,287 | | |
| | |
保修
责任 |
| |||
2020年12月31日的余额
|
| | | $ | — | | |
新增内容: | | | | | | | |
或有付款凭证
|
| | | | 3,743 | | |
配售代理授权书
|
| | | | 362 | | |
权证负债公允价值变动
|
| | | | 182 | | |
2021年6月30日的余额(未经审计)
|
| | | $ | 4,287 | | |
| | |
06月30日
2021 |
| |
12月31日
2020 |
| ||||||
| | |
(未审核)
|
| | ||||||||
应计费用: | | | | | | | | | | | | | |
应计员工薪酬
|
| | | $ | 1,948 | | | | | $ | 2,041 | | |
研发 - 许可费
|
| | | | 8,000 | | | | | | — | | |
应计应付版税
|
| | | | 3,340 | | | | | | 2,682 | | |
累计优惠券和返点
|
| | | | 18,609 | | | | | | 12,869 | | |
退货保证金
|
| | | | 2,099 | | | | | | 2,580 | | |
其他
|
| | | | 1,368 | | | | | | 1,326 | | |
应计费用合计
|
| | | $ | 35,364 | | | | | $ | 21,498 | | |
| | |
2021年6月30日
|
| |||||||||||||||||||||
| | |
西米诺(1)
|
| |
Accutane(2)
|
| |
止痒
产品(3) |
| |
合计
|
| ||||||||||||
分期付款 - 许可证,短期
|
| | | $ | 2,000 | | | | | $ | 1,000 | | | | | $ | 1,500 | | | | | $ | 4,500 | | |
少:计入利息
|
| | | | (517) | | | | | | (101) | | | | | | (21) | | | | | | (639) | | |
分期付款小计 - 许可证,短期
|
| | | | 1,483 | | | | | | 899 | | | | | | 1,479 | | | | | | 3,861 | | |
分期付款 - 许可证,长期
|
| | | | 5,000 | | | | | | 2,000 | | | | | | — | | | | | | 7,000 | | |
少:计入利息
|
| | | | (519) | | | | | | (46) | | | | | | — | | | | | | (565) | | |
分期付款 - 许可证小计,长期
|
| | | | 4,481 | | | | | | 1,954 | | | | | | — | | | | | | 6,435 | | |
分期付款 - 许可证合计
|
| | | $ | 5,964 | | | | | $ | 2,853 | | | | | $ | 1,479 | | | | | $ | 10,296 | | |
| | |
2020年12月31日
|
| |||||||||||||||||||||
| | |
西米诺(1)
|
| |
Accutane(2)
|
| |
止痒
产品(3) |
| |
合计
|
| ||||||||||||
分期付款 - 许可证,短期
|
| | | $ | 2,000 | | | | | $ | 500 | | | | | $ | 2,800 | | | | | $ | 5,300 | | |
少:计入利息
|
| | | | (602) | | | | | | (122) | | | | | | (54) | | | | | | (778) | | |
分期付款小计 - 许可证,短期
|
| | | | 1,398 | | | | | | 378 | | | | | | 2,746 | | | | | | 4,522 | | |
分期付款 - 许可证,长期
|
| | | | 5,000 | | | | | | 3,000 | | | | | | 1,000 | | | | | | 9,000 | | |
少:计入利息
|
| | | | (775) | | | | | | (88) | | | | | | — | | | | | | (863) | | |
分期付款 - 许可证小计,长期
|
| | | | 4,225 | | | | | | 2,912 | | | | | | 1,000 | | | | | | 8,137 | | |
分期付款 - 许可证合计
|
| | | $ | 5,623 | | | | | $ | 3,290 | | | | | $ | 3,746 | | | | | $ | 12,659 | | |
| | |
主体
|
| |
归罪
利息 |
| |
笔记总数
应付 |
| |||||||||
截至2021年12月31日的6个月
|
| | | $ | 2,500 | | | | | $ | (341) | | | | | $ | 2,159 | | |
2022年12月31日
|
| | | | 5,000 | | | | | | (490) | | | | | | 4,510 | | |
2023年12月31日
|
| | | | 2,500 | | | | | | (276) | | | | | | 2,224 | | |
2024年12月31日
|
| | | | 1,500 | | | | | | (97) | | | | | | 1,403 | | |
合计
|
| | | $ | 11,500 | | | | | $ | (1,204) | | | | | $ | 10,296 | | |
| | |
截止三个月
06月30日 |
| |
截至6个月
06月30日 |
| ||||||||||||||||||
| | |
2021
|
| |
2020
|
| |
2021
|
| |
2020
|
| ||||||||||||
租赁成本 | | | | | | | | | | | | | | | | | | | | | | | | | |
运营租赁成本
|
| | | $ | 21 | | | | | $ | 24 | | | | | $ | 44 | | | | | $ | 47 | | |
可变租赁成本
|
| | | | 1 | | | | | | — | | | | | | 2 | | | | | | — | | |
总租赁成本
|
| | | $ | 22 | | | | | $ | 24 | | | | | $ | 46 | | | | | $ | 47 | | |
| | |
截至6个月
06月30日 |
| |||||||||
|
2021
|
| |
2020
|
| ||||||||
营业租赁的营业现金流
|
| | | $ | 44 | | | | | $ | 47 | | |
加权平均剩余租赁期限 - 运营租赁
|
| | | | 1.2 | | | | | | 0.5 | | |
加权平均贴现率 - 运营租赁
|
| | | | 4.0% | | | | | | 6.0% | | |
| | |
未来租赁
责任 |
| |||
截至2021年12月31日的6个月
|
| | | $ | 48 | | |
截至2022年12月31日的年度
|
| | | | 100 | | |
合计
|
| | | | 148 | | |
减去:现值折扣
|
| | | | (5) | | |
经营性租赁负债
|
| | | $ | 143 | | |
(千美元)
|
| |
截至6月30日的6个月
|
| |||||||||||||||||||||||||||||||||
|
2021
|
| |
2020
|
| ||||||||||||||||||||||||||||||||
|
利息
|
| |
费用
|
| |
合计
|
| |
利息
|
| |
费用
|
| |
合计
|
| ||||||||||||||||||||
可转换优先股
|
| | | | — | | | | | | 270 | | | | | | 270 | | | | | | — | | | | | | — | | | | | | — | | |
转换溢价
|
| | | | 584 | | | | | | — | | | | | | 584 | | | | | | — | | | | | | — | | | | | | — | | |
可转换优先股应付利息
|
| | | | 263 | | | | | | — | | | | | | 263 | | | | | | — | | | | | | — | | | | | | — | | |
分期付款 - 许可证
|
| | | | 441 | | | | | | — | | | | | | 441 | | | | | | 305 | | | | | | — | | | | | | 305 | | |
EWB费用
|
| | | | 5 | | | | | | — | | | | | | 5 | | | | | | — | | | | | | — | | | | | | — | | |
利息费用和融资费合计
|
| | | $ | 1,293 | | | | | $ | 270 | | | | | $ | 1,563 | | | | | $ | 305 | | | | | $ | — | | | | | $ | 305 | | |
(千美元)
|
| |
截至6月30日的三个月
|
| |||||||||||||||||||||||||||||||||
|
2021
|
| |
2020
|
| ||||||||||||||||||||||||||||||||
|
利息
|
| |
费用
|
| |
合计
|
| |
利息
|
| |
费用
|
| |
合计
|
| ||||||||||||||||||||
可转换优先股
|
| | | | — | | | | | | 270 | | | | | | 270 | | | | | | — | | | | | | — | | | | | | — | | |
转换溢价
|
| | | | 584 | | | | | | — | | | | | | 584 | | | | | | — | | | | | | — | | | | | | — | | |
可转换优先股应付利息
|
| | | | 263 | | | | | | — | | | | | | 263 | | | | | | — | | | | | | — | | | | | | — | | |
分期付款 - 许可证
|
| | | | 220 | | | | | | — | | | | | | 220 | | | | | | 155 | | | | | | — | | | | | | 155 | | |
EWB费用
|
| | | | 5 | | | | | | — | | | | | | 5 | | | | | | — | | | | | | — | | | | | | — | | |
利息费用和融资费合计
|
| | | $ | 1,072 | | | | | $ | 270 | | | | | $ | 1,342 | | | | | $ | 155 | | | | | $ | — | | | | | $ | 155 | | |
| | |
数量
个共享 |
| |
加权
平均 行权价 |
| |
加权总和
平均 内在值 |
| |
加权
平均 剩余 合同 寿命(年) |
| ||||||||||||
2020年12月31日的优秀期权
|
| | | | 2,142,000 | | | | | $ | 0.80 | | | | | $ | 7,934,320 | | | | | | 5.72 | | |
锻炼
|
| | | | (10,000) | | | | | | 0.68 | | | | | | | | | | | | | | |
被没收
|
| | | | (17,666) | | | | | | 1.36 | | | | | | | | | | | | | | |
2021年6月30日的未偿还期权
|
| | | | 2,114,334 | | | | | $ | 0.79 | | | | | $ | 7,840,679 | | | | | | 5.20 | | |
已授予并可行使的期权
|
| | | | 1,978,416 | | | | | $ | 0.75 | | | | | $ | 7,415,011 | | | | | | 5.02 | | |
| | |
数量
个单位 |
| |
加权
平均 行权价 |
| ||||||
2020年12月31日未归属余额
|
| | | | 815,524 | | | | | $ | 3.37 | | |
被没收
|
| | | | (95,000) | | | | | | 3.37 | | |
2021年6月30日未归属余额
|
| | | | 720,524 | | | | | $ | 3.37 | | |
| | |
截止三个月
06月30日 |
| |
截至6个月
06月30日 |
| ||||||||||||||||||
|
2021
|
| |
2020
|
| |
2021
|
| |
2020
|
| ||||||||||||||
Targadox® | | | | $ | 5,727 | | | | | $ | 6,514 | | | | | $ | 12,926 | | | | | $ | 14,981 | | |
Ximino® | | | | | 1,312 | | | | | | 2,074 | | | | | | 3,413 | | | | | | 4,823 | | |
Exelderm® | | | | | 1,736 | | | | | | 864 | | | | | | 2,953 | | | | | | 1,687 | | |
Accutane® | | | | | 1,945 | | | | | | — | | | | | | 2,141 | | | | | | — | | |
Qbrexza® | | | | | 4,568 | | | | | | — | | | | | | 4,568 | | | | | | — | | |
其他品牌收入
|
| | | | — | | | | | | (37) | | | | | | 6 | | | | | | (130) | | |
产品总收入
|
| | | $ | 15,288 | | | | | $ | 9,415 | | | | | $ | 26,007 | | | | | $ | 21,361 | | |
| | |
这三个和
截至6个月 2021年6月30日 |
| |||
未授予的限制性股票单位/奖励
|
| | | | 720,524 | | |
未归属期权
|
| | | | 2,114,334 | | |
总潜在稀释效应
|
| | | | 2,834,858 | | |
| | |
三个月
|
| |
六个月
|
| ||||||
|
截至2020年6月30日
|
| |||||||||||
净收入
|
| | | $ | 455 | | | | | $ | 2,752 | | |
加权平均流通股 - Basic
|
| | | | 9,133,333 | | | | | | 9,133,333 | | |
股票期权
|
| | | | 1,699,657 | | | | | | 1,692,946 | | |
加权平均流通股 - 稀释
|
| | | | 10,832,990 | | | | | | 10,826,279 | | |
每股数据: | | | | | | | | | | | | | |
基础版
|
| | | $ | 0.05 | | | | | $ | 0.30 | | |
稀释
|
| | | $ | 0.04 | | | | | $ | 0.25 | | |
| | |
12月31日
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
资产 | | | | | | | | | | | | | |
流动资产 | | | | | | | | | | | | | |
现金
|
| | | $ | 8,246 | | | | | $ | 4,801 | | |
扣除准备金后的应收账款
|
| | | | 23,928 | | | | | | 18,955 | | |
库存
|
| | | | 1,404 | | | | | | 857 | | |
预付费用和其他流动资产
|
| | | | 1,664 | | | | | | 655 | | |
流动资产总额
|
| | | | 35,242 | | | | | | 25,268 | | |
长期资产 | | | | | | | | | | | | | |
财产和设备,净额
|
| | | | — | | | | | | 5 | | |
无形资产净值
|
| | | | 15,029 | | | | | | 7,377 | | |
经营性租赁使用权资产,净额
|
| | | | 175 | | | | | | 84 | | |
递延税金资产
|
| | | | 1,454 | | | | | | 1,119 | | |
其他资产
|
| | | | 6 | | | | | | 6 | | |
长期资产总额
|
| | | | 16,664 | | | | | | 8,591 | | |
总资产
|
| | | $ | 51,906 | | | | | $ | 33,859 | | |
负债和股东权益
|
| | | | | | | | | | | | |
流动负债 | | | | | | | | | | | | | |
应付帐款
|
| | | $ | 1,839 | | | | | $ | 2,043 | | |
应收账款、关联方
|
| | | | 117 | | | | | | 65 | | |
应计费用
|
| | | | 21,498 | | | | | | 18,706 | | |
分期付款 - 许可证,短期(扣除778美元的债务折扣后为零)
2020年12月31日和2019年12月31日) |
| | | | 4,522 | | | | | | — | | |
短期经营租赁负债
|
| | | | 85 | | | | | | 83 | | |
流动负债总额
|
| | | | 28,061 | | | | | | 20,897 | | |
应付所得税 | | | | | 99 | | | | | | — | | |
应付票据关联方
|
| | | | 5,220 | | | | | | 5,220 | | |
分期付款 - 许可证,长期(扣除863美元和2,010美元的债务折扣)
2020年12月31日和2019年12月31日) |
| | | | 8,137 | | | | | | 4,990 | | |
长期经营租赁负债
|
| | | | 97 | | | | | | — | | |
总负债
|
| | | | 41,614 | | | | | | 31,107 | | |
承付款和或有事项(附注10) | | | | | | | | | | | | | |
股东权益 | | | | | | | | | | | | | |
普通股,面值0.0001美元,授权股份5000万股
|
| | | | | | | | | | | | |
截至2020年12月31日和2019年12月31日,已发行和已发行普通股分别为3,151,333股和3,133,333股
|
| | | | — | | | | | | — | | |
普通股 - A类,截至2020年12月31日和2019年12月31日已发行和已发行股票600万股
|
| | | | 1 | | | | | | 1 | | |
新增实收资本
|
| | | | 5,171 | | | | | | 2,914 | | |
留存收益(累计亏损)
|
| | | | 5,120 | | | | | | (163) | | |
股东权益总额
|
| | | | 10,292 | | | | | | 2,752 | | |
总负债和股东权益
|
| | | $ | 51,906 | | | | | $ | 33,859 | | |
| | |
截至2013年12月31日的年度
|
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
产品收入,净额
|
| | | $ | 44,531 | | | | | $ | 34,921 | | |
运营费用 | | | | | | | | | | | | | |
- 产品销售成本产品收入
|
| | | | 14,594 | | | | | | 10,532 | | |
销售、一般和行政
|
| | | | 22,086 | | | | | | 19,130 | | |
总运营费用
|
| | | | 36,680 | | | | | | 29,662 | | |
运营收入
|
| | | | 7,851 | | | | | | 5,259 | | |
其他费用 | | | | | | | | | | | | | |
利息支出
|
| | | | 698 | | | | | | 255 | | |
其他费用合计
|
| | | | 698 | | | | | | 255 | | |
所得税前收入
|
| | | | 7,153 | | | | | | 5,004 | | |
所得税费用
|
| | | | 1,870 | | | | | | 1,379 | | |
净收入
|
| | | $ | 5,283 | | | | | $ | 3,625 | | |
每股普通股净收入 - Basic
|
| | | $ | 0.58 | | | | | $ | 0.40 | | |
稀释后的每股普通股净收入 -
|
| | | $ | 0.49 | | | | | $ | 0.36 | | |
加权平均流通股 - Basic
|
| | | | 9,135,985 | | | | | | 9,133,333 | | |
加权平均流通股 - 稀释
|
| | | | 10,836,122 | | | | | | 10,075,804 | | |
| | |
普通股
|
| |
普通股A
|
| |
其他
实收 大写 |
| |
保留
收入 (累计 赤字) |
| |
合计
股东的 股权 (赤字) |
| |||||||||||||||||||||||||||
|
个共享
|
| |
金额
|
| |
个共享
|
| |
金额
|
| ||||||||||||||||||||||||||||||||
截至2019年1月1日的余额
|
| | | | 3,133,333 | | | | | $ | — | | | | | | 6,000,000 | | | | | $ | 1 | | | | | $ | 1,491 | | | | | $ | (3,788) | | | | | $ | (2,296) | | |
股票薪酬
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 240 | | | | | | — | | | | | | 240 | | |
出资额 - 清偿关联方应付
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 1,183 | | | | | | — | | | | | | 1,183 | | |
净收入
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 3,625 | | | | | | 3,625 | | |
截至2019年12月31日的余额
|
| | | | 3,133,333 | | | | | $ | — | | | | | | 6,000,000 | | | | | $ | 1 | | | | | $ | 2,914 | | | | | $ | (163) | | | | | $ | 2,752 | | |
股票薪酬
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 153 | | | | | | — | | | | | | 153 | | |
行使现金期权
|
| | | | 18,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | 13 | | | | | | — | | | | | | 13 | | |
出资额 - 清偿关联方应付
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 2,091 | | | | | | — | | | | | | 2,091 | | |
净收入
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 5,283 | | | | | | 5,283 | | |
截至2020年12月31日的余额
|
| | | | 3,151,333 | | | | | $ | — | | | | | | 6,000,000 | | | | | $ | 1 | | | | | $ | 5,171 | | | | | $ | 5,120 | | | | | $ | 10,292 | | |
| | |
截至的年度
12月31日 |
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
经营活动的现金流 | | | | | | | | | | | | | |
净收入
|
| | | $ | 5,283 | | | | | $ | 3,625 | | |
调整以调整净亏损与经营活动提供的净收益: | | | | | | | | | | | | | |
折旧费
|
| | | | 5 | | | | | | 5 | | |
坏账支出
|
| | | | 49 | | | | | | 100 | | |
非现金利息支出
|
| | | | 698 | | | | | | 255 | | |
许可费摊销
|
| | | | 1,420 | | | | | | 1,174 | | |
经营性租赁使用权资产摊销
|
| | | | 91 | | | | | | 85 | | |
股票薪酬
|
| | | | 153 | | | | | | 240 | | |
递延所得税
|
| | | | (335) | | | | | | 69 | | |
经营性资产和负债变动:
|
| | | | | | | | | | | | |
应收账款
|
| | | | (5,022) | | | | | | (10,492) | | |
库存
|
| | | | (547) | | | | | | (179) | | |
预付费用和其他流动资产
|
| | | | (1,009) | | | | | | 404 | | |
应付帐款
|
| | | | (204) | | | | | | 1,083 | | |
应收账款、关联方
|
| | | | 52 | | | | | | 65 | | |
应计费用
|
| | | | 2,390 | | | | | | 11,651 | | |
应付所得税
|
| | | | 2,191 | | | | | | 1,019 | | |
租赁负债
|
| | | | (83) | | | | | | (86) | | |
经营活动提供的净现金
|
| | | | 5,132 | | | | | | 9,018 | | |
投资活动产生的现金流 | | | | | | | | | | | | | |
购买无形资产
|
| | | | (1,200) | | | | | | (2,400) | | |
投资活动使用的净现金
|
| | | | (1,200) | | | | | | (2,400) | | |
融资活动产生的现金流 | | | | | | | | | | | | | |
期权行使收益
|
| | | | 13 | | | | | | — | | |
支付应付许可证票据
|
| | | | (500) | | | | | | — | | |
支付堡垒票据
|
| | | | — | | | | | | (4,000) | | |
《堡垒笔记》收益
|
| | | | — | | | | | | 449 | | |
融资活动使用的净现金
|
| | | | (487) | | | | | | (3,551) | | |
现金净增长
|
| | | | 3,445 | | | | | | 3,067 | | |
期初现金
|
| | | | 4,801 | | | | | | 1,734 | | |
期末现金
|
| | | $ | 8,246 | | | | | $ | 4,801 | | |
补充披露现金流信息: | | | | | | | | | | | | | |
缴纳所得税的现金
|
| | | $ | 110 | | | | | $ | 192 | | |
补充披露非现金融资和投资活动: | | | | | | | | | | | | | |
无形资产收购应付票据
|
| | | $ | 7,872 | | | | | $ | 4,734 | | |
关联方应缴出资额 - 清偿
|
| | | $ | 2,091 | | | | | $ | 1,183 | | |
| | |
截至12月31日
|
| |||||||||
|
2020
|
| |
2019
|
| ||||||||
成品
|
| | | $ | 1,404 | | | | | $ | 857 | | |
总库存
|
| | | $ | 1,404 | | | | | $ | 857 | | |
| | |
使用寿命
(年) |
| |
截至12月31日
|
| ||||||||||||
|
2020
|
| |
2019
|
| ||||||||||||||
租赁改进
|
| | | | 2 | | | | | $ | 11 | | | | | $ | 11 | | |
减去:累计折旧
|
| | | | | | | | | | (11) | | | | | | (6) | | |
财产和设备,净额
|
| | | | | | | | | $ | — | | | | | $ | 5 | | |
| | |
预计有用
|
| |
截至12月31日
|
| ||||||||||||
|
寿命(年)
|
| |
2020
|
| |
2019
|
| |||||||||||
Ceracade® | | | | | 3 | | | | | $ | 300 | | | | | $ | 300 | | |
Luxamendate® | | | | | 3 | | | | | | 50 | | | | | | 50 | | |
Targadox® | | | | | 3 | | | | | | 1,250 | | | | | | 1,250 | | |
Ximino®(1) | | | | | 7 | | | | | | 7,134 | | | | | | 7,134 | | |
Exelderm® | | | | | 3 | | | | | | 1,600 | | | | | | 1,200 | | |
Accutane®(2) | | | | | 5 | | | | | | 4,727 | | | | | | — | | |
止痒产品(3)
|
| | | | 3 | | | | | | 3,945 | | | | | | — | | |
合计
|
| | | | | | | | | | 19,006 | | | | | | 9,934 | | |
减去:累计摊销
|
| | | | | | | | | | (3,977) | | | | | | (2,557) | | |
无形资产净值
|
| | | | | | | | | $ | 15,029 | | | | | $ | 7,377 | | |
| | |
Ximino®
|
| |
Exelderm®
|
| |
Accutane®
|
| |
合计
摊销 |
| ||||||||||||
2021年12月31日
|
| | | $ | 1,019 | | | | | $ | 667 | | | | | $ | 788 | | | | | $ | 2,074 | | |
2022年12月31日
|
| | | | 1,019 | | | | | | — | | | | | | 945 | | | | | | 1,964 | | |
2023年12月31日
|
| | | | 1,019 | | | | | | — | | | | | | 945 | | | | | | 1,964 | | |
2024年12月31日
|
| | | | 1,019 | | | | | | — | | | | | | 945 | | | | | | 1,964 | | |
2025年12月31日
|
| | | | 1,019 | | | | | | — | | | | | | 945 | | | | | | 1,964 | | |
此后
|
| | | | 595 | | | | | | — | | | | | | 159 | | | | | | 754 | | |
小计
|
| | | $ | 5,690 | | | | | $ | 667 | | | | | $ | 4,727 | | | | | $ | 11,084 | | |
尚未投入使用的资产
|
| | | | — | | | | | | — | | | | | | — | | | | | | 3,945 | | |
合计
|
| | | $ | 5,690 | | | | | $ | 667 | | | | | $ | 4,727 | | | | | $ | 15,029 | | |
| | |
截至12月31日
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
应计费用: | | | | | | | | | | | | | |
应计员工薪酬
|
| | | $ | 2,041 | | | | | $ | 1,762 | | |
应计应付版税
|
| | | | 2,682 | | | | | | 2,320 | | |
累计优惠券和返点
|
| | | | 12,869 | | | | | | 9,291 | | |
应计退货准备金
|
| | | | 2,580 | | | | | | 4,516 | | |
其他
|
| | | | 1,326 | | | | | | 817 | | |
应计费用合计
|
| | | $ | 21,498 | | | | | $ | 18,706 | | |
| | |
主体
|
| |
计入利息
折扣 |
| |
笔记总数
应付 |
| |||||||||
2021年12月31日
|
| | | $ | 5,300 | | | | | $ | (778) | | | | | $ | 4,522 | | |
2022年12月31日
|
| | | | 5,000 | | | | | | (490) | | | | | | 4,510 | | |
2023年12月31日
|
| | | | 2,500 | | | | | | (276) | | | | | | 2,224 | | |
2024年12月31日
|
| | | | 1,500 | | | | | | (97) | | | | | | 1,403 | | |
合计
|
| | | $ | 14,300 | | | | | $ | (1,641) | | | | | $ | 12,659 | | |
| | |
截至2013年12月31日的年度
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
运营租赁成本
|
| | | $ | 94 | | | | | $ | 94 | | |
可变租赁成本
|
| | | | 6 | | | | | | 4 | | |
总租赁成本
|
| | | $ | 100 | | | | | $ | 98 | | |
| | |
截至2013年12月31日的年度
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
营业租赁的营业现金流
|
| | | $ | 86 | | | | | $ | 94 | | |
用使用权资产交换新的经营租赁负债
|
| | | | 182 | | | | | | — | | |
加权平均剩余租赁期限 - 运营租赁
|
| | | | 1.5 | | | | | | 1.0 | | |
加权平均贴现率 - 运营租赁
|
| | | | 5.0% | | | | | | 6.0% | | |
| | |
未来租赁责任
|
| |||
截至2021年12月31日的年度
|
| | | $ | 91 | | |
截至2022年12月31日的年度
|
| | | | 100 | | |
合计
|
| | | | 191 | | |
减去:现值折扣
|
| | | | (9) | | |
经营性租赁负债
|
| | | $ | 182 | | |
|
无风险利率
|
| |
1.85% – 2.09%
|
|
|
预期股息收益率
|
| |
—
|
|
|
三年内的预期期限
|
| |
5.0 – 10.0
|
|
|
预期波动率
|
| |
111.43% – 112.03%
|
|
|
无风险利率
|
| | | | 2.49% | | |
|
预期股息收益率
|
| | | | — | | |
|
三年内的预期期限
|
| | | | 4.0 | | |
|
预期波动率
|
| | | | 75% | | |
| | |
数量
个共享 |
| |
加权
平均 行使价 |
| |
合计
加权 平均 内在价值 |
| |
加权
平均 剩余 合同 寿命(年) |
| ||||||||||||
截至2018年12月31日的未偿还期权
|
| | | | 2,050,000 | | | | | $ | 0.72 | | | | | $ | 1,382,450 | | | | | | 7.39 | | |
已批准
|
| | | | 285,000 | | | | | | 1.39 | | | | | | — | | | | | | — | | |
被没收
|
| | | | (41,000) | | | | | | 1.20 | | | | | | 52,156 | | | | | | — | | |
截至2019年12月31日的未偿还期权
|
| | | | 2,294,000 | | | | | | 0.79 | | | | | $ | 5,916,970 | | | | | | 6.73 | | |
锻炼
|
| | | | (18,000) | | | | | | 0.69 | | | | | | 29,428 | | | | | | — | | |
被没收
|
| | | | (134,000) | | | | | | 0.72 | | | | | | 325,359 | | | | | | — | | |
截至2020年12月31日的未偿还期权
|
| | | | 2,142,000 | | | | | $ | 0.80 | | | | | $ | 7,934,320 | | | | | | 5.72 | | |
截至2020年12月31日已授予并可行使的期权
|
| | | | 1,865,083 | | | | | $ | 0.72 | | | | | $ | 7,046,658 | | | | | | 5.38 | | |
| | |
单位数
|
| |
加权
平均 行使价 |
| ||||||
2019年12月31日未归属余额
|
| | | | — | | | | | $ | — | | |
已批准
|
| | | | 845,524 | | | | | | 3.37 | | |
被没收
|
| | | | (30,000) | | | | | | 3.37 | | |
2020年12月31日未归属余额
|
| | | | 815,524 | | | | | $ | 3.37 | | |
| | |
12月31日
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Targadox® | | | | $ | 30,708 | | | | | $ | 28,068 | | |
Ximino® | | | | | 9,518 | | | | | | 3,642 | | |
Exelderm® | | | | | 4,453 | | | | | | 2,867 | | |
其他品牌收入
|
| | | | (148) | | | | | | 344 | | |
产品总收入,净额
|
| | | $ | 44,531 | | | | | $ | 34,921 | | |
| | |
截至2013年12月31日的年度
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
电流: | | | | | | | | | | | | | |
联邦政府
|
| | | $ | 1,669 | | | | | $ | 1,110 | | |
状态
|
| | | | 536 | | | | | | 200 | | |
总电流
|
| | | | 2,205 | | | | | | 1,310 | | |
延期: | | | | | | | | | | | | | |
联邦政府
|
| | | | (234) | | | | | | (28) | | |
状态
|
| | | | (101) | | | | | | 97 | | |
合计延期
|
| | | | (335) | | | | | | 69 | | |
所得税总费用
|
| | | $ | 1,870 | | | | | $ | 1,379 | | |
| | |
截至12月31日
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
递延税金资产: | | | | | | | | | | | | | |
净营业亏损结转
|
| | | $ | 5 | | | | | $ | 46 | | |
许可费摊销
|
| | | | 1,086 | | | | | | 905 | | |
股票薪酬
|
| | | | 113 | | | | | | 128 | | |
租赁责任
|
| | | | 48 | | | | | | 21 | | |
销售退货、折扣和坏账准备金
|
| | | | 765 | | | | | | 1,119 | | |
应计项目和准备金
|
| | | | 248 | | | | | | 40 | | |
递延税金资产总额
|
| | | | 2,265 | | | | | | 2,259 | | |
递延纳税义务: | | | | | | | | | | | | | |
第481(A)节销售退货、贴现和坏账准备金调整
|
| | | | (765) | | | | | | (1,119) | | |
使用权资产
|
| | | | (46) | | | | | | (21) | | |
递延税金资产净额
|
| | | $ | 1,454 | | | | | $ | 1,119 | | |
| | |
截至2013年12月31日的年度
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
税前收入百分比: | | | | | | | | | | | | | |
美国联邦法定所得税税率
|
| | | | 21% | | | | | | 21% | | |
扣除联邦福利后的州税
|
| | | | 6% | | | | | | 3% | | |
不可抵扣项目
|
| | | | 0% | | | | | | 1% | | |
规定返回
|
| | | | 0% | | | | | | 1% | | |
状态速率更改
|
| | | | -1% | | | | | | 0% | | |
其他
|
| | | | 0% | | | | | | 2% | | |
实际所得税率
|
| | | | 26% | | | | | | 28% | | |
| | |
截至2013年12月31日的年度
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
净收入
|
| | | $ | 5,283 | | | | | $ | 3,625 | | |
加权平均流通股 - Basic
|
| | | | 9,135,985 | | | | | | 9,133,333 | | |
股票期权
|
| | | | 1,700,137 | | | | | | 942,471 | | |
加权平均流通股 - 稀释
|
| | | | 10,836,122 | | | | | | 10,075,804 | | |
每股数据: | | | | | | | | | | | | | |
基础版
|
| | | $ | 0.58 | | | | | $ | 0.40 | | |
稀释
|
| | | $ | 0.49 | | | | | $ | 0.36 | | |